Modifications in Cardiovascular Risk Factors When Performing Physical Exercise in Hypertensive and Dyslipidemic Patients (ACTIVA)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Therapeutic physical exercise
No physical exercise
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Blood Pressure monitoring, Primary care, Physical exercises, Training intensity
Eligibility Criteria
Inclusion Criteria:
- Age between 40 and 65 years.
- Under treatment with at least one antihypertensive drug for hypertension. Treatment should have lasted at least 12 months prior to inclusion in the study.
- Diagnosed with dyslipidemia under pharmacological treatment or with a specific hypercholesterolemia (> 200 mg/dL) in the past and a cholesterol level at the start of the study greater than 200 mg/dL.
- Patient in Primary Prevention.
- Subjects who do not develop physical exercise scheduled on a weekly basis.
- Subjects who have given written informed consent to participate in the study.
Exclusion Criteria:
- Serious or terminal illnesses.
- Diagnosis of ischemic and/or cerebrovascular heart disease.
- Presence of chronic diseases that prevent the performance of a physical exercise program or a stress test (disabling arthropathies, chronic moderate/severe pneumopathies, arrhythmias, etc).
- Severe mental illnesses: psychosis, severe depressive disorder, neurosis.
- Diabetes mellitus.
- Presence of absolute or relative contraindications dictated by the American College of Sports Medicine (ACSM, 1995), during the performance of the stress tests.
- Pregnant or breast-feeding women
- Inability to understand the informed consent.
Sites / Locations
- Catholic University of Murcia
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
High intensity training (HIT) group
Low-moderate intensity training (LMIT) group
No training group
Arm Description
The HIT group performed the exercises with loads at 80-90% of HRF.
The HIT group performed the exercises with the loads at 50-70% of the HRF
They did not perform any type of programmed physical exercise during the study.
Outcomes
Primary Outcome Measures
Ambulatory blood pressure monitoring
Blood pressure is measured with a holter
Secondary Outcome Measures
Systolic blood pressure
Blood pressure is measured with a holter
Diastolic blood pressure
Blood pressure is measured with a holter
Mean blood pressure
Blood pressure is measured with a holter
Pulse pressure
Blood pressure is measured with a holter
Lipid profile
Blood samples
Antihypertensive medication
Record of medication and dosage
Lipid lowering medication
Record of medication and dosage
Control of dietary intake
Diet source
Muscle function
Isokinetic dynamometry.
Balance
Force platform Kistler
Aerobic function
Modified Balke-Ware protocol on a rolling mat
Framingham tables by category
Physicians Global Assessment to measure cardiovascular risk
Full Information
NCT ID
NCT04832048
First Posted
March 31, 2021
Last Updated
April 2, 2021
Sponsor
Universidad Católica San Antonio de Murcia
1. Study Identification
Unique Protocol Identification Number
NCT04832048
Brief Title
Modifications in Cardiovascular Risk Factors When Performing Physical Exercise in Hypertensive and Dyslipidemic Patients
Acronym
ACTIVA
Official Title
Comparative Clinical Trial on the Modifications of Cardiovascular Risk Factors When Performing Different Therapeutic Physical Exercise Programs With Different Intensities in Hypertensive and Dyslipidemic Patients.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
September 20, 2016 (Actual)
Primary Completion Date
June 12, 2017 (Actual)
Study Completion Date
December 20, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad Católica San Antonio de Murcia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Single-center, randomized, parallel-group, controlled, open-label study. The aim of the study was to evaluate the effects of an exercise training program intervention of different intensities (high intensity versus low-moderate intensity) on blood pressure reduction as a complementary strategy in hypertensive individuals being treated with at least one antihypertensive drug.
Detailed Description
All participants included in the study were referred by their primary care physicians, who prescribed physical exercise as a healthy lifestyle intervention added to the antihypertensive regimens in the framework of the "ACTIVA-Murcia Program".
Participants in the HIT and LMIT groups followed the same physical training program, with the only difference being the intensity of the training. The program included two phases of physical exercise lasting 12 weeks and 16 weeks, respectively, separated by a 7-week rest period, which coincided with a holiday period. The times of both phases were not equal in terms of duration, since it is a community physical exercise program established by the Region of Murcia, and does not depend on the researchers.
The program was developed by graduates in Physical Activity and Sport Sciences, who were in charge of teaching the exercises and supervised each training session.
Participants assigned to the HIT and LMIT groups were given guidelines to continue physical exercise during the 7-week rest period, while participants in the control group were offered to participate in the program after the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Blood Pressure monitoring, Primary care, Physical exercises, Training intensity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A single-center, randomized, parallel-group, controlled, and open-label study was conducted.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
High intensity training (HIT) group
Arm Type
Experimental
Arm Description
The HIT group performed the exercises with loads at 80-90% of HRF.
Arm Title
Low-moderate intensity training (LMIT) group
Arm Type
Experimental
Arm Description
The HIT group performed the exercises with the loads at 50-70% of the HRF
Arm Title
No training group
Arm Type
Placebo Comparator
Arm Description
They did not perform any type of programmed physical exercise during the study.
Intervention Type
Other
Intervention Name(s)
Therapeutic physical exercise
Intervention Description
The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.
Intensity was be determined by Maximum Heart Rate (HRF).
Intervention Type
Other
Intervention Name(s)
No physical exercise
Intervention Description
No programmed physical exercise
Primary Outcome Measure Information:
Title
Ambulatory blood pressure monitoring
Description
Blood pressure is measured with a holter
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Secondary Outcome Measure Information:
Title
Systolic blood pressure
Description
Blood pressure is measured with a holter
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Diastolic blood pressure
Description
Blood pressure is measured with a holter
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Mean blood pressure
Description
Blood pressure is measured with a holter
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Pulse pressure
Description
Blood pressure is measured with a holter
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Lipid profile
Description
Blood samples
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Antihypertensive medication
Description
Record of medication and dosage
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Lipid lowering medication
Description
Record of medication and dosage
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Control of dietary intake
Description
Diet source
Time Frame
A nutritional registry will be carried out. The nutritional intake of three days in two periods will be collected. One record at the beginning and another at the end, that is, six days.
Title
Muscle function
Description
Isokinetic dynamometry.
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Balance
Description
Force platform Kistler
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Aerobic function
Description
Modified Balke-Ware protocol on a rolling mat
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Title
Framingham tables by category
Description
Physicians Global Assessment to measure cardiovascular risk
Time Frame
Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age between 40 and 65 years.
Under treatment with at least one antihypertensive drug for hypertension. Treatment should have lasted at least 12 months prior to inclusion in the study.
Diagnosed with dyslipidemia under pharmacological treatment or with a specific hypercholesterolemia (> 200 mg/dL) in the past and a cholesterol level at the start of the study greater than 200 mg/dL.
Patient in Primary Prevention.
Subjects who do not develop physical exercise scheduled on a weekly basis.
Subjects who have given written informed consent to participate in the study.
Exclusion Criteria:
Serious or terminal illnesses.
Diagnosis of ischemic and/or cerebrovascular heart disease.
Presence of chronic diseases that prevent the performance of a physical exercise program or a stress test (disabling arthropathies, chronic moderate/severe pneumopathies, arrhythmias, etc).
Severe mental illnesses: psychosis, severe depressive disorder, neurosis.
Diabetes mellitus.
Presence of absolute or relative contraindications dictated by the American College of Sports Medicine (ACSM, 1995), during the performance of the stress tests.
Pregnant or breast-feeding women
Inability to understand the informed consent.
Facility Information:
Facility Name
Catholic University of Murcia
City
Murcia
ZIP/Postal Code
30107
Country
Spain
12. IPD Sharing Statement
Learn more about this trial
Modifications in Cardiovascular Risk Factors When Performing Physical Exercise in Hypertensive and Dyslipidemic Patients
We'll reach out to this number within 24 hrs